ATE462444T1 - Immunogene zusammensetzung - Google Patents

Immunogene zusammensetzung

Info

Publication number
ATE462444T1
ATE462444T1 AT06754596T AT06754596T ATE462444T1 AT E462444 T1 ATE462444 T1 AT E462444T1 AT 06754596 T AT06754596 T AT 06754596T AT 06754596 T AT06754596 T AT 06754596T AT E462444 T1 ATE462444 T1 AT E462444T1
Authority
AT
Austria
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Application number
AT06754596T
Other languages
German (de)
English (en)
Inventor
Ralph Biemans
Jan Poolman
Pierre Duvivier
Philippe Denoel
Carine Capiau
Dominique Boutriau
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36716943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE462444(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513071.1A external-priority patent/GB0513071D0/en
Priority claimed from GBGB0513069.5A external-priority patent/GB0513069D0/en
Priority claimed from GB0515556A external-priority patent/GB0515556D0/en
Priority claimed from GB0524204A external-priority patent/GB0524204D0/en
Priority claimed from GB0526041A external-priority patent/GB0526041D0/en
Priority claimed from GB0526040A external-priority patent/GB0526040D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE462444T1 publication Critical patent/ATE462444T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Surgical Instruments (AREA)
AT06754596T 2005-06-27 2006-06-23 Immunogene zusammensetzung ATE462444T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB0513071.1A GB0513071D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GBGB0513069.5A GB0513069D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GB0515556A GB0515556D0 (en) 2005-07-28 2005-07-28 Immunogenic composition
GB0524204A GB0524204D0 (en) 2005-11-28 2005-11-28 Immunogenic composition
GB0526041A GB0526041D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526040A GB0526040D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
PCT/EP2006/006210 WO2007000322A1 (en) 2005-06-27 2006-06-23 Immunogenic composition

Publications (1)

Publication Number Publication Date
ATE462444T1 true ATE462444T1 (de) 2010-04-15

Family

ID=36716943

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06754596T ATE462444T1 (de) 2005-06-27 2006-06-23 Immunogene zusammensetzung
AT06754611T ATE516816T1 (de) 2005-06-27 2006-06-23 Verfahren zur herstellung von impfstoffen
AT06754599T ATE536884T1 (de) 2005-06-27 2006-06-23 Immunogene zusammensetzung

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT06754611T ATE516816T1 (de) 2005-06-27 2006-06-23 Verfahren zur herstellung von impfstoffen
AT06754599T ATE536884T1 (de) 2005-06-27 2006-06-23 Immunogene zusammensetzung

Country Status (36)

Country Link
US (13) US9789179B2 (h)
EP (11) EP1896065B2 (h)
JP (9) JP5037503B2 (h)
KR (7) KR101359953B1 (h)
CN (3) CN102526723B (h)
AP (1) AP2436A (h)
AR (3) AR053935A1 (h)
AT (3) ATE462444T1 (h)
AU (7) AU2006263936B2 (h)
BE (1) BE2012C042I2 (h)
BR (5) BRPI0612655B1 (h)
CA (5) CA2611964C (h)
CY (5) CY1109996T1 (h)
DE (1) DE602006013313D1 (h)
DK (7) DK1896065T4 (h)
EA (4) EA012528B1 (h)
ES (9) ES2662651T3 (h)
FR (1) FR22C1008I2 (h)
HR (4) HRP20110567T4 (h)
HU (7) HUE056842T2 (h)
IL (8) IL187924A (h)
LT (2) LT2351578T (h)
LU (2) LU92085I2 (h)
MA (4) MA29602B1 (h)
MX (5) MX2007016237A (h)
MY (3) MY148110A (h)
NL (1) NL300549I2 (h)
NO (4) NO345422B1 (h)
NZ (6) NZ564371A (h)
PE (6) PE20110096A1 (h)
PL (8) PL2283857T3 (h)
PT (8) PT2351578T (h)
SI (8) SI2283857T1 (h)
TW (5) TWI477283B (h)
UA (2) UA95237C2 (h)
WO (6) WO2007000327A1 (h)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180316A1 (en) * 2000-06-29 2003-09-25 Dominique Boutriau Multivalent vaccine composition
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
AP2436A (en) 2005-06-27 2012-08-31 Glaxosmithkline Biolog Sa Immunogenic composition
RU2457858C2 (ru) * 2005-09-01 2012-08-10 Новартис Вэксинес Энд Дайэгностикс Гмбх Унд Ко Кг Множественная вакцинация, включающая менингококки серогруппы с
AU2012261764B2 (en) * 2005-09-01 2016-09-08 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup C meningococcus
PT1973564T (pt) 2005-12-22 2017-01-24 Glaxosmithkline Biologicals Sa Vacina compreendendo conjugados polissacarídicos capsulares de streptococcus pneumoniae
CA2646993C (en) 2006-03-22 2016-01-26 Novartis Ag Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
CA2662051A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
BRPI0813644B8 (pt) * 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
EA201100268A1 (ru) * 2008-08-28 2011-10-31 Глаксосмитклайн Байолоджикалс С.А. Вакцина
JP5689064B2 (ja) 2008-10-27 2015-03-25 ノバルティス アーゲー 精製方法
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
NZ593674A (en) 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
JP5593626B2 (ja) * 2009-03-31 2014-09-24 凸版印刷株式会社 計量スプーン
KR20120034612A (ko) 2009-04-14 2012-04-12 노파르티스 아게 황색 포도상구균에 대한 면역화를 위한 조성물
ES2552153T3 (es) * 2009-04-30 2015-11-26 Coley Pharmaceutical Group, Inc. Vacuna neumocócica y usos de la misma
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
RU2531234C2 (ru) * 2009-06-22 2014-10-20 ВАЙЕТ ЭлЭлСи КОНЪЮГАТ ПОЛИСАХАРИД-БЕЛОК ДЛЯ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ЗАЩИТЫ ПРОТИВ ИНФЕКЦИИ Staphylococcus aureus, СПОСОБЫ ПОЛУЧЕНИЯ КОНЪЮГАТА (ВАРИАНТЫ), КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОНЪЮГАТ И СПОСОБЫ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ Staphylococcus aureus
SG176837A1 (en) 2009-06-22 2012-01-30 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
JP2013504556A (ja) 2009-09-10 2013-02-07 ノバルティス アーゲー 気道疾患に対する組み合わせワクチン
EP3199177A1 (en) 2009-10-30 2017-08-02 GlaxoSmithKline Biologicals S.A. Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
ES2639035T5 (en) 2010-08-23 2025-09-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
BR112013005329A2 (pt) 2010-09-10 2017-05-02 Wyeth Llc variantes não lipidadas de antígenos orf2086 de neisseria meningitidis
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
ES2681698T3 (es) 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Vacunas de combinación con menores dosis de antígeno y/o adyuvante
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
JP2013112653A (ja) * 2011-11-30 2013-06-10 Jnc Corp 新規重合体およびその製造方法
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
BR112014016223A8 (pt) 2011-12-29 2017-07-04 Novartis Ag combinações adjuvantes de proteínas de ligação de fator h meningocócico
CN104302315B (zh) * 2012-01-30 2018-02-06 印度血清研究所私人有限公司 免疫原性组合物及其制备方法
AU2013214105A1 (en) 2012-02-02 2014-07-24 Novartis Ag Promoters for increased protein expression in meningococcus
CN102569723A (zh) * 2012-02-13 2012-07-11 华为技术有限公司 锂离子电池正极材料及其制备方法、正极及锂离子电池
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
MX372965B (es) 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
JP2015509963A (ja) 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン
EP2822583A2 (en) 2012-03-09 2015-01-14 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
ITMI20121597A1 (it) 2012-09-25 2014-03-26 Beta Pharma S A Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
CN105307684A (zh) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 非直链糖缀合物
EP2925355B1 (en) 2012-11-30 2017-11-15 GlaxoSmithKline Biologicals S.A. Pseudomonas antigens and antigen combinations
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
US20150320852A1 (en) 2012-12-18 2015-11-12 Glaxosmithkline Biologicals Sa Conjugates for protecting against diphtheria and/or tetanus
JP6411378B2 (ja) 2013-02-01 2018-10-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｔｏｌｌ様受容体アゴニストを含む免疫学的組成物の皮内送達
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
CA2903322C (en) 2013-03-18 2023-09-05 Glaxosmithkline Biologicals S.A. A method of immunising against neisseria meningitidis infection
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
IN2014DE02450A (h) 2013-09-25 2015-06-26 Suzuki Motor Corp
RU2535122C1 (ru) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения холерогена-анатоксина
CN110859957B (zh) * 2014-01-21 2024-04-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
US10407703B2 (en) 2014-04-17 2019-09-10 Medizinische Hochschule Hannover Means and methods for producing Neisseria meningitidis capsular polysaccharides of low dispersity
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
TWI720448B (zh) * 2015-07-21 2021-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
US20170333546A1 (en) * 2015-12-08 2017-11-23 Jl Medical Corporation Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein
MY199399A (en) * 2016-03-15 2023-10-25 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Novel polysaccharide-protein conjugates and process to obtain thereof
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
EP3506935B1 (en) 2016-09-02 2024-01-10 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
HRP20191966T4 (hr) 2016-09-13 2022-09-16 Allergan, Inc. Stabilizirani neproteinski klostridijalni pripravci toksina
EP3530285B1 (en) * 2016-10-20 2023-08-09 KM Biologics Co., Ltd. METHOD FOR PRODUCING HIB CONJUGATE VACCINE USING PRP WITH
LOWERED MOLECULAR WEIGHT
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
JP7218358B2 (ja) 2017-09-07 2023-02-06 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
WO2019145981A1 (en) * 2018-01-29 2019-08-01 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司（Us） 脑膜炎奈瑟氏菌组合物及其方法
US20220387614A1 (en) 2019-11-22 2022-12-08 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
BR112023009109A2 (pt) 2020-11-13 2024-02-06 Glaxosmithkline Biologicals Sa Carreadores de proteína bacteriana e métodos de conjugação
RU2770877C1 (ru) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
WO2025021704A1 (en) 2023-07-21 2025-01-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB513069A (en) 1937-04-24 1939-10-03 Linde Air Prod Co Improvements in method of and apparatus for the treatment of metallic bodies by oxidising gas
GB505518A (en) 1938-02-03 1939-05-12 Daniel Morgan Skeins Improvements in or relating to envelopes
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4123520A (en) * 1977-08-01 1978-10-31 Merck & Co., Inc. Method for preparing high molecular weight meningococcal Group C vaccine
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4235994A (en) * 1978-06-26 1980-11-25 Merck & Co., Inc. High molecular weight meningococcal group C vaccine and method for preparation thereof
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
DE3040825A1 (de) * 1980-10-30 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach Neues tridekapeptid, verfahren zu seiner herstellung und verwendung
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
NL8500370A (nl) * 1984-02-22 1985-09-16 Sandoz Ag Diazepinoindolen, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten.
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3526940A1 (de) 1985-07-27 1987-02-12 Siegfried Fricker Anker zum einbetonieren in schwere lasten
IL78929A0 (en) 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US5180815A (en) * 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
US5115924A (en) 1988-05-31 1992-05-26 Beatrice Konig-Haug Shelf system
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
FI920131A0 (fi) 1989-07-14 1992-01-13 Praxis Biolog Inc Cytokin- och hormonbaerare foer konjugatvaccin.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DE69019164T2 (de) 1989-12-14 1995-09-07 National Research Council Of Canada, Ottawa, Ontario Verbessertes meningokokkale polysaccharidkonjugatvakzin.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
GB2264352A (en) 1992-01-31 1993-08-25 Richards Eng Ltd Incineration apparatus
AU685047B2 (en) 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
ATE178907T1 (de) 1992-05-06 1999-04-15 Harvard College Rezeptorbindende region des diphtherietoxius
DK0642355T3 (da) 1992-05-23 1998-11-30 Smithkline Beecham Biolog Kombinerede vacciner, der omfatter hepatitis B-overfladeantigen og andre antigener
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ATE176157T1 (de) 1992-10-27 1999-02-15 American Cyanamid Co Pädiatrische kombinationsvakzine mit verbesserter immunogenizität jeder vakzine komponente
CA2128895C (en) 1992-12-14 1999-04-13 John M. Crowell Removable piston bore liner for hydraulically actuated seismic vibrator
US5849301A (en) 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
ES2308962T3 (es) † 1995-06-07 2008-12-16 Glaxosmithkline Biologicals S.A. Vacunas que comprenden un conjugado de antigeno polisacarido-proteina transportadora y una proteina transportadora libre.
CZ288908B6 (cs) 1995-06-23 2001-09-12 Smithkline Beecham Biologicals S. A. Kombinovaná vakcína, tato vakcína ve formě sady, způsob její výroby a její použití
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
DE69712219T2 (de) 1996-10-23 2002-12-12 Matsushita Electric Industrial Co., Ltd. Optische platte
AU6909098A (en) 1996-10-31 1998-05-22 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
AU1420897A (en) 1996-12-18 1998-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugate vaccine for (salmonella paratyphi) a
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
WO1999013906A1 (en) 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
AU760669B2 (en) * 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
CA2340692A1 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
WO2000033882A1 (en) † 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
EP2050464B1 (en) 1998-12-21 2019-08-07 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
CA2363141C (en) 1999-02-26 2010-04-06 Chiron Corporation Microemulsions with adsorbed macromolecules and microparticles
CN1191852C (zh) * 1999-03-19 2005-03-09 史密丝克莱恩比彻姆生物有限公司 疫苗
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
JP4660043B2 (ja) 1999-06-25 2011-03-30 ワイス・ホールディングズ・コーポレイション グラム陰性細菌のペプチドグリカン結合リポタンパク質の脂質化された形態の製造
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
CA2393298C (en) 1999-12-02 2011-02-01 Chiron Corporation Compositions and methods for stabilizing biological molecules upon lyophilization
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US20030180316A1 (en) * 2000-06-29 2003-09-25 Dominique Boutriau Multivalent vaccine composition
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
MXPA03000822A (es) * 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP2189473A3 (en) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Nucleic and proteins from streptococcus groups A & B
SI21352A (sl) 2001-01-23 2004-06-30 Aventis Pasteur Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
US6615062B2 (en) 2001-05-31 2003-09-02 Infraredx, Inc. Referencing optical catheters
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
IL163988A0 (en) * 2002-03-15 2005-12-18 Wyeth Corp Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
DK1490409T3 (da) * 2002-03-26 2009-03-23 Novartis Vaccines & Diagnostic Modificerede saccharider med forbedret stabilitet i vand
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
ATE513560T1 (de) 2002-05-14 2011-07-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoff gegen bakterielle meningitis, der über die schleimhaut appliziert wird
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
WO2004011027A1 (en) 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
GB0220199D0 (en) 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
US20060057160A1 (en) 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
PT2351579T (pt) 2002-10-11 2016-12-22 Novartis Vaccines And Diagnostics S R L Vacinas polipeptídicas para proteção ampla contra linhagens meningocócicas hipervirulentas
CN1401328A (zh) 2002-10-18 2003-03-12 北京绿竹生物技术有限责任公司 流行性脑脊髓膜炎多糖－蛋白结合疫苗
HUE034801T2 (en) * 2002-11-01 2018-02-28 Glaxosmithkline Biologicals Sa Drying procedure
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CN1168501C (zh) 2002-12-27 2004-09-29 北京绿竹生物技术有限责任公司 一种多糖-蛋白结合疫苗
CA2514328C (en) * 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
MXPA05009579A (es) 2003-03-13 2005-11-17 Glaxosmithkline Biolog Sa Proceso de purificacion para citolisina bacteriana.
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
BRPI0410341B8 (pt) 2003-05-07 2021-05-25 Sanofi Pasteur Inc conjugados de polissacarídeo-proteína derivatizados de meningococos multivalentes e vacina
ATE437633T2 (de) 2003-06-02 2009-08-15 Novartis Vaccines & Diagnostic Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
BRPI0411875A (pt) 2003-06-23 2006-08-08 Sanofi Pasteur Inc método de imunização contra os sorogrupos a e c de neisseria meningitidis
KR101034055B1 (ko) 2003-07-18 2011-05-12 엘지이노텍 주식회사 발광 다이오드 및 그 제조방법
CA2535043A1 (en) * 2003-08-06 2005-04-28 Ellen Jessouroun Process for preparing polysaccharide-protein conjugate vaccines
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
WO2005022583A2 (en) * 2003-08-21 2005-03-10 Applera Corporation Reduction of matrix interference for maldi mass spectrometry analysis
PL1961426T3 (pl) * 2003-10-02 2012-03-30 Gsk Vaccines S R L Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych
DE602004028262D1 (de) * 2003-10-02 2010-09-02 Glaxosmithkline Biolog Sa B. pertussis antigene und ihre verwendung bei der vakzinierung
WO2005064021A2 (en) 2003-12-23 2005-07-14 Glaxosmithkline Biologicals S.A. Vaccine
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
PT1742659E (pt) * 2004-04-05 2013-06-03 Pah Usa 15 Llc Emulsões de óleo em água microfluidizadas e composições de vacinas
WO2005105140A2 (en) 2004-04-30 2005-11-10 Chiron Srl Meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
BRPI0515516B1 (pt) * 2004-09-22 2017-08-08 Glaxosmithkline Biologicals S.A. Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition.
US20060121055A1 (en) 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
WO2006089264A2 (en) * 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
PT1868645E (pt) 2005-04-08 2012-05-17 Wyeth Llc Composição conjugada de polissacárido-proteína pneumocócica polivalente
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
PL1885734T3 (pl) 2005-05-06 2015-08-31 Novartis Ag Immunogeny dla szczepionek przeciwko Meningitidis-A
AP2436A (en) 2005-06-27 2012-08-31 Glaxosmithkline Biolog Sa Immunogenic composition
CN1709505B (zh) 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
RU2457858C2 (ru) * 2005-09-01 2012-08-10 Новартис Вэксинес Энд Дайэгностикс Гмбх Унд Ко Кг Множественная вакцинация, включающая менингококки серогруппы с
US8679770B2 (en) 2005-09-05 2014-03-25 Glaxo Smith Kline Biologicals S.A. Serum bactericidal assay for N. meningitidis specific antisera
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PT1973564T (pt) * 2005-12-22 2017-01-24 Glaxosmithkline Biologicals Sa Vacina compreendendo conjugados polissacarídicos capsulares de streptococcus pneumoniae
US20080305127A1 (en) 2005-12-23 2008-12-11 Glaxosmithkline Biologicals S.A. Conjugate Vaccines
CA2644724C (en) * 2006-03-17 2016-05-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing complex multivalent immunogenic conjugates
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
JP2009531387A (ja) * 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
NZ573931A (en) * 2006-06-29 2012-03-30 Craig J Venter Inst Inc Polypeptides from neisseria meningitidis
US7491517B2 (en) * 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
ZA200900379B (en) 2006-07-21 2010-08-25 Univ California Human endogenous retrovirus polypeptide compositions and methods of use thereof
CA2662051A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
GB0700135D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
WO2008111374A1 (ja) 2007-03-14 2008-09-18 Konica Minolta Business Technologies, Inc. 情報埋め込み方法、そのプログラムおよび情報埋め込み装置
KR20100017569A (ko) 2007-05-02 2010-02-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP2152302B1 (en) 2007-06-04 2015-10-07 GlaxoSmithKline Biologicals SA Formulation of meningitis vaccines
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EA201100268A1 (ru) 2008-08-28 2011-10-31 Глаксосмитклайн Байолоджикалс С.А. Вакцина
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
WO2011138636A1 (en) * 2009-09-30 2011-11-10 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN103124737A (zh) * 2010-03-11 2013-05-29 葛兰素史密丝克莱恩生物有限公司 针对革兰氏阴性菌例如奈瑟菌属感染或疾病的免疫原性组合物或疫苗
CN102781322B (zh) 2010-06-11 2015-02-25 松下电器产业株式会社 语音听取的评价系统、及方法
WO2013068949A1 (en) * 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
GB2495341B (en) * 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
CN104302315B (zh) * 2012-01-30 2018-02-06 印度血清研究所私人有限公司 免疫原性组合物及其制备方法
AU2013265336A1 (en) 2012-05-22 2014-12-04 Novartis Ag Meningococcus serogroup X conjugate
WO2014001328A1 (en) 2012-06-25 2014-01-03 Nadiro A/S A lifeboat deployment unit
PL3513806T3 (pl) * 2012-12-05 2023-05-15 Glaxosmithkline Biologicals Sa Imunogenna kompozycja
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
EA201790239A1 (ru) * 2014-08-05 2017-07-31 Глаксосмитклайн Байолоджикалс С.А. Молекула-носитель для антигенов
TWI715617B (zh) * 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP3506935B1 (en) * 2016-09-02 2024-01-10 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
US11951165B2 (en) * 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
AU2018215585B2 (en) * 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11179453B2 (en) * 2017-07-18 2021-11-23 Serum Institute Of India Pvt Ltd Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof

Also Published As

Publication number Publication date
US20150044253A1 (en) 2015-02-12
PE20070499A1 (es) 2007-05-21
NZ564370A (en) 2011-10-28
AR056397A1 (es) 2007-10-10
CN103083657A (zh) 2013-05-08
JP5297800B2 (ja) 2013-09-25
IL188045A0 (en) 2008-03-20
DK1896063T3 (da) 2012-03-19
AU2006263965B2 (en) 2012-09-13
BRPI0612655B1 (pt) 2021-06-15
EP2878307A1 (en) 2015-06-03
LT2351578T (lt) 2017-04-10
WO2007000341A3 (en) 2007-05-31
TWI422386B (zh) 2014-01-11
UA95238C2 (uk) 2011-07-25
PL3009146T3 (pl) 2022-02-07
ES2750243T3 (es) 2020-03-25
EA200702574A1 (ru) 2008-06-30
US8883163B2 (en) 2014-11-11
CA2611964A1 (en) 2007-01-04
MY147490A (en) 2012-12-14
BE2012C042I2 (h) 2021-07-19
EP2283857A1 (en) 2011-02-16
MA29602B1 (fr) 2008-07-01
EP2351578A1 (en) 2011-08-03
IL188072A (en) 2017-07-31
HK1206587A1 (en) 2016-01-15
EP3009146A1 (en) 2016-04-20
US9358279B2 (en) 2016-06-07
US20130171188A1 (en) 2013-07-04
NO345305B1 (no) 2020-12-07
WO2007000341A2 (en) 2007-01-04
PT1896061T (pt) 2019-08-01
MY148110A (en) 2013-02-28
HK1116414A1 (en) 2008-12-24
PL1896061T3 (pl) 2020-02-28
ES2377075T5 (es) 2016-04-29
EP1896064A2 (en) 2008-03-12
IL187924A0 (en) 2008-03-20
HUE045482T2 (hu) 2019-12-30
PL1896065T5 (pl) 2014-12-31
BRPI0612656A8 (pt) 2018-01-23
AU2006263964A1 (en) 2007-01-04
JP2013209395A (ja) 2013-10-10
AU2006263936B2 (en) 2010-05-20
IL188072A0 (en) 2008-03-20
IL188046A (en) 2012-03-29
TW201336507A (zh) 2013-09-16
KR101359953B1 (ko) 2014-02-21
US20200000911A1 (en) 2020-01-02
CY1112698T1 (el) 2016-02-10
KR20130086087A (ko) 2013-07-30
SI1896062T1 (sl) 2010-07-30
EP1896062B1 (en) 2010-03-31
PE20110096A1 (es) 2011-03-07
NZ564371A (en) 2010-05-28
PT3009146T (pt) 2021-11-30
EP2351578B1 (en) 2017-01-18
PE20070123A1 (es) 2007-02-08
PL1896063T3 (pl) 2012-04-30
LTPA2012019I1 (lt) 2012-11-26
UA95237C2 (uk) 2011-07-25
JP2013107913A (ja) 2013-06-06
BRPI0612669B8 (pt) 2021-05-25
DK1896061T3 (da) 2019-08-26
KR20080018216A (ko) 2008-02-27
PT2351578T (pt) 2017-04-07
EP1896065B2 (en) 2014-09-03
NL300549I2 (h) 2017-01-03
HUE047211T2 (hu) 2020-04-28
NZ590204A (en) 2012-02-24
EA200702577A1 (ru) 2008-06-30
WO2007000343A3 (en) 2007-05-31
JP5718960B2 (ja) 2015-05-13
BRPI0612670A2 (pt) 2010-11-30
PL1896062T3 (pl) 2010-08-31
JP2015134829A (ja) 2015-07-27
SI3009146T1 (sl) 2022-02-28
TW200730187A (en) 2007-08-16
ATE516816T1 (de) 2011-08-15
MA29603B1 (fr) 2008-07-01
SI1896063T1 (sl) 2012-03-30
EP3009146B1 (en) 2021-10-20
NZ564607A (en) 2011-06-30
US8329184B2 (en) 2012-12-11
HK1116413A1 (en) 2008-12-24
EA012506B1 (ru) 2009-10-30
EP1896065B1 (en) 2011-07-20
ES2898451T3 (es) 2022-03-07
IL188046A0 (en) 2008-03-20
KR20080018226A (ko) 2008-02-27
NO344452B1 (no) 2019-12-09
AU2010203115C1 (en) 2013-05-02
HK1114011A1 (en) 2008-10-24
MX2007016405A (es) 2008-03-07
NZ564605A (en) 2011-01-28
SI2351578T1 (sl) 2017-05-31
US10245317B2 (en) 2019-04-02
AU2006263965A1 (en) 2007-01-04
BRPI0612669B1 (pt) 2019-08-13
KR101321056B1 (ko) 2013-10-30
PT1896062E (pt) 2010-05-17
AU2010203115A1 (en) 2010-08-12
MX2007016236A (es) 2008-03-07
CN102218138A (zh) 2011-10-19
US8846049B2 (en) 2014-09-30
EP2201961B1 (en) 2018-01-24
IL214657A0 (en) 2011-09-27
DE602006013313D1 (de) 2010-05-12
US9789179B2 (en) 2017-10-17
CY2012027I2 (el) 2015-10-07
NO342815B1 (no) 2018-08-13
TWI477283B (zh) 2015-03-21
EP1896066B8 (en) 2022-01-19
KR20130122810A (ko) 2013-11-08
ES2662651T3 (es) 2018-04-09
HUS000497I2 (hu) 2021-03-29
WO2007000314A3 (en) 2007-05-31
US20080199490A1 (en) 2008-08-21
EP2201961A1 (en) 2010-06-30
PE20142165A1 (es) 2015-01-09
US20170065714A1 (en) 2017-03-09
SI1896065T2 (sl) 2014-12-31
CY2012027I1 (el) 2015-10-07
ATE536884T1 (de) 2011-12-15
AR056396A1 (es) 2007-10-10
SI2878307T1 (sl) 2019-11-29
EP1896063B1 (en) 2011-12-14
EP2283857B1 (en) 2019-07-24
HUS1200023I1 (hu) 2021-03-29
US9486515B2 (en) 2016-11-08
AU2006263963A1 (en) 2007-01-04
PE20110072A1 (es) 2011-02-04
IL213718A (en) 2013-07-31
WO2007000342A3 (en) 2007-05-31
LU92085I2 (fr) 2012-12-19
CY1109996T1 (el) 2014-09-10
PL1896065T3 (pl) 2011-12-30
JP2008543909A (ja) 2008-12-04
PT2283857T (pt) 2019-10-24
CN103083657B (zh) 2016-06-08
MX2007016237A (es) 2008-03-07
FR22C1008I2 (fr) 2024-01-19
AU2006263944A1 (en) 2007-01-04
BRPI0612655A8 (pt) 2018-01-30
BRPI0612670B1 (pt) 2020-04-28
US20130004532A1 (en) 2013-01-03
JP2013018798A (ja) 2013-01-31
TW200738259A (en) 2007-10-16
US9931397B2 (en) 2018-04-03
EP1896063A1 (en) 2008-03-12
JP2008543904A (ja) 2008-12-04
WO2007000342A8 (en) 2008-07-10
BRPI0612669A2 (pt) 2010-11-30
MX2007016403A (es) 2008-03-07
CN102526723A (zh) 2012-07-04
CA2611964C (en) 2016-11-08
BRPI0612654B8 (pt) 2021-05-25
CA2612957A1 (en) 2007-01-04
MA29993B1 (fr) 2008-12-01
CA2611960A1 (en) 2007-01-04
BRPI0612654A2 (pt) 2012-10-02
AU2006263963B2 (en) 2010-05-13
CA2612957C (en) 2016-07-19
AU2006263936A1 (en) 2007-01-04
HUE031380T2 (en) 2017-07-28
EP1896063B2 (en) 2016-03-02
HRP20110567T1 (en) 2011-09-30
WO2007000342A2 (en) 2007-01-04
US8431136B2 (en) 2013-04-30
ES2741529T3 (es) 2020-02-11
DK1896065T3 (da) 2011-08-29
EA012528B1 (ru) 2009-10-30
PL2283857T3 (pl) 2020-02-28
HRP20120102T1 (hr) 2012-02-29
DK2878307T3 (da) 2019-10-07
KR101351873B1 (ko) 2014-02-17
SI2283857T1 (sl) 2019-11-29
PL2351578T3 (pl) 2017-07-31
CN102526723B (zh) 2017-07-07
JP5769688B2 (ja) 2015-08-26
CA2611960C (en) 2015-05-05
US20190298822A1 (en) 2019-10-03
SI1896065T1 (sl) 2011-10-28
NO345422B1 (no) 2021-01-25
MX2007016402A (es) 2008-03-07
HRP20110567T4 (xx) 2015-01-16
JP5731737B2 (ja) 2015-06-10
CA2612963A1 (en) 2007-01-04
EA013374B1 (ru) 2010-04-30
WO2007000343A2 (en) 2007-01-04
TWI537001B (zh) 2016-06-11
DK1896062T3 (da) 2010-06-28
PT2878307T (pt) 2019-10-24
US20090136541A1 (en) 2009-05-28
AU2006263964B2 (en) 2010-05-20
NZ564606A (en) 2010-10-29
TWI407970B (zh) 2013-09-11
JP5037503B2 (ja) 2012-09-26
DK1896065T4 (da) 2014-10-20
IL213718A0 (en) 2011-07-31
ES2340711T3 (es) 2010-06-08
BRPI0612656A2 (pt) 2010-11-30
BRPI0612656B1 (pt) 2021-09-08
CA2612963C (en) 2016-10-18
AU2006263944B2 (en) 2012-03-01
JP2008543905A (ja) 2008-12-04
AU2010203115B2 (en) 2012-03-15
KR20080025184A (ko) 2008-03-19
PE20070163A1 (es) 2007-03-01
KR20080030577A (ko) 2008-04-04
KR101408113B1 (ko) 2014-06-16
KR101351870B1 (ko) 2014-02-17
CY1118646T1 (el) 2017-07-12
NO20076302L (no) 2008-03-26
PL2878307T3 (pl) 2020-01-31
ES2901378T3 (es) 2022-03-22
BRPI0612670B8 (pt) 2021-05-25
US10166287B2 (en) 2019-01-01
US20180064806A1 (en) 2018-03-08
SI1896061T1 (sl) 2019-10-30
EA200702575A1 (ru) 2008-06-30
EP1896065A2 (en) 2008-03-12
DK2351578T3 (en) 2017-04-24
EP1896061A2 (en) 2008-03-12
WO2007000327A1 (en) 2007-01-04
LTC1896065I2 (lt) 2025-06-10
EP1896066A2 (en) 2008-03-12
LUC00247I2 (h) 2024-10-04
MY147783A (en) 2013-01-31
KR101532068B1 (ko) 2015-06-29
EA012214B1 (ru) 2009-08-28
ES2747025T3 (es) 2020-03-09
AP2436A (en) 2012-08-31
NO20076363L (no) 2008-03-26
EP1896062A1 (en) 2008-03-12
CA2612980C (en) 2019-01-15
AU2010212417A1 (en) 2010-09-09
US20090041802A1 (en) 2009-02-12
IL222346A (en) 2015-07-30
US8398983B2 (en) 2013-03-19
IL213795A (en) 2013-05-30
JP5280199B2 (ja) 2013-09-04
EP1896061B1 (en) 2019-06-12
HRP20100211T1 (hr) 2010-05-31
HUE046905T2 (hu) 2020-03-30
MA29569B1 (fr) 2008-06-02
EA200702576A1 (ru) 2008-06-30
KR20080024222A (ko) 2008-03-17
US20100215686A1 (en) 2010-08-26
CA2612980A1 (en) 2007-01-04
NO20076350L (no) 2008-03-26
BRPI0612654B1 (pt) 2021-05-04
AP2007004274A0 (en) 2007-12-31
US11241495B2 (en) 2022-02-08
CY1111827T1 (el) 2015-10-07
NO20076343L (no) 2008-03-25
EP2878307B1 (en) 2019-07-24
EP1896066B1 (en) 2021-10-27
PT1896065E (pt) 2011-08-31
JP2008543907A (ja) 2008-12-04
HRP20170457T1 (hr) 2017-05-19
AR053935A1 (es) 2007-05-23
BRPI0612655A2 (pt) 2010-11-30
US20080193476A1 (en) 2008-08-14
JP5965512B2 (ja) 2016-08-03
LU92085I9 (h) 2019-01-04
HUS2200002I1 (hu) 2022-12-28
PT1896063E (pt) 2012-02-13
HUE056842T2 (hu) 2022-03-28
IL187924A (en) 2011-11-30
IL213795A0 (en) 2011-07-31
FR22C1008I1 (fr) 2022-04-29
DK2283857T3 (da) 2019-10-28
US20090252759A1 (en) 2009-10-08
JP2008543908A (ja) 2008-12-04
WO2007000322A1 (en) 2007-01-04
WO2007000314A2 (en) 2007-01-04
TW201414490A (zh) 2014-04-16
ES2621780T3 (es) 2017-07-05
ES2377075T3 (es) 2012-03-22

Similar Documents

Publication Publication Date Title
FR22C1008I2 (fr) Composition immunogène
MA28994B1 (fr) Composition immunogene
EP1923431A4 (en) Curable composition
EP1967540A4 (en) HARDENING COMPOSITION
EP1788047A4 (en) WATER REPELLENT / OIL-REPELLING COMPOSITION
NO20055686D0 (no) Sammensetning
EP1970411A4 (en) HARDENING COMPOSITION
DE502006006590D1 (de) Biozide zusammensetzungen
DE602006010127D1 (de) Härtbare Zusammensetzung
EP1854446A4 (en) ANTIALLERGIC COMPOSITION
GB0526038D0 (en) Immunogenic composition
DE602005017191D1 (de) Geruchsreduzierte waschstück-zusammensetzung
FR2871686B1 (fr) Composition anti-decoloration
FI20055583A0 (fi) Vaihtosuuntaajakokoonpano
GB0513071D0 (en) Immunogenic composition
FR2882656B1 (fr) Composition antitabagique
ATE536394T1 (de) Härtbare zusammensetzung
ATE539120T1 (de) Härtbare zusammensetzung
ATE545680T1 (de) Härtbare zusammensetzung
FI7048U1 (fi) Sahakokoonpano
ATE474879T1 (de) Flammwidrige zusammensetzung
SE0400205D0 (sv) Composition
GB0526041D0 (en) Immunogenic composition
GB0515556D0 (en) Immunogenic composition
GB0524204D0 (en) Immunogenic composition

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1896062

Country of ref document: EP